ADMA Biologics, Inc. Financials

Market Capitalization $4.36 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	21.76
Forward PE	25.39
Price to Sales TTM	$9.50
Price to Book MRQ	$11.68
Enterprise to Revenue	9.49
Enterprise to EBITDA	27.25

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	45.01%
Operating Margin	30.38%
Return on Assets TTM	22.06%
Return on Equity TTM	78.45%

Income Statement

Revenue TTM	$459,380,992
Revenue per Share TTM	$1.95
Quarterly Revenue Growth	40.20%
Gross Profit TTM	$241,542,000
EBITDA	$160,799,000
Net Income to Common TTM	$206,771,008
Diluted EPS TTM	$0.84
Quarterly Earnings Growth YoY	51.10%

Balance Sheet

Total Cash MRQ	$71,625,000
Total Cash per Share MRQ	$0.30
Total Debt MRQ	$
Total Debt to Equity MRQ	21.96
Current Ratio MRQ	6.58
Book Value per Share MRQ	$1.57

Cash Flow

Operating Cash Flow TTM	$101,215,000
Levered Free Cash Flow TTM	$52,615,876

ADMA Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	236,620,545
Float Shares	234,169,647
Avg 10 Volume	3,759,670
Avg 30 Volume	None
Shares Short	13,806,018
Short Ratio	5.43
Short % of Shares	7.10%
% Held by Insiders	2.59%
% Held by Institutions	88.42%

Stock Price Summary

Beta	0.47
Fifty Two Week Low	$10.21
Fifty Two Week High	$25.67
Fifty Two Week Change	37.31%
Day 50 MA	$20.42
Day 200 MA	$18.87

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date